Foghorn Therapeutics Inc.
FHTX
$3.87
$0.164.31%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -5.53% | -11.08% | 17.12% | 21.95% | 24.71% |
| Total Depreciation and Amortization | -71.22% | 5.39% | 16.23% | 7.59% | -0.96% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -23.08% | 189.97% | 17.38% | -39.71% | -18.73% |
| Change in Net Operating Assets | 11.84% | -1.00% | -32.52% | 20.08% | -0.34% |
| Cash from Operations | -5.42% | 9.17% | 10.21% | 17.77% | 18.32% |
| Capital Expenditure | -- | 100.00% | 100.00% | -29.41% | 72.28% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -160.21% | -41.89% | 158.31% | 288.53% | 8.21% |
| Cash from Investing | -160.27% | -40.64% | 158.02% | 288.23% | 8.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 35,934.53% | 14,425.00% | -96.60% | -99.75% | -88.09% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 35,707.19% | 14,425.00% | -95.34% | -99.75% | -88.09% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 21.81% | -280.31% | 120.63% | -78.07% | 614.50% |